CD19- CD34t metabolically programmed CAR T-cell therapy (Medical University of South Carolina)

N/A

Report date: 2023/01/29 20:00:19

Base Information

Drug NameCD19- CD34t metabolically programmed CAR T-cell therapy (Medical University of South Carolina)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMedical University Of South Carolina

China Registration ClassN/A

Develop Information

Active CompaniesMedical University Of South Carolina

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A